{"url_path":"/sec/bngo/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1411690/0001411690-26-000027-index.html","accession_number":"0001411690-26-000027","cik":"0001411690","ticker":"BNGO","issuer_name":"Bionano Genomics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1411690/0001411690-26-000027-index.html","primary_entity_key":"0001411690","primary_entity_name":"Bionano Genomics, Inc."},"word_count":155,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\nOn May 13 2026, Bionano Genomics, Inc. (the “Company”) issued a press release reporting its financial results for the first quarter ended March 31, 2026. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.\n\nIn accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated into this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K."}